Dr. Jared R. Brosch, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- Indiana University School of Medicine (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 465
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: Indiana University School of Medicine
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
IN license 01073639A
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Indiana University Health Indianapolis, IN
- Indiana University Health Bloomington Hospital Bloomington, IN
- Indiana University Health Ball Memorial Hospital Muncie, IN
- Indiana University Health North Hospital Carmel, IN
Medical groups
- Iu Health Medical Group LLC (4,462 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 465
- Services billed
- 966
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 406 | 300 |
| New patient office or other outpatient visit, 60-74 minutes | 91 | 91 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 45 | 32 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 40 | 40 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 38 | 26 |
| Established patient office or other outpatient visit, 40-54 minutes | 29 | 29 |
| Removal of cerebrospinal fluid with lower back spinal tap for diagnostic test | 19 | 19 |
| Assessment of and care planning for patient with impaired thought processing, typically 60 minutes | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 16 payments worth $33,212 in total to this clinician.
| Lilly USA, LLC | $12,372 |
|---|---|
| AbbVie Inc. | $7,299 |
| Eli Lilly and Company | $6,575 |
| Eisai Inc. | $3,619 |
| Roche Diagnostics Corporation | $3,348 |
| Consulting Fee | $25,956 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $6,575 |
| Travel and Lodging | $555 |
| Food and Beverage | $127 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Lilly USA, LLC Oct 31, 2025 | Consulting Fee KISUNLA · Neuroscience | $9,375 |
| AbbVie Inc. Feb 10, 2025 | Consulting Fee | $7,200 |
| Eli Lilly and Company Nov 17, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,625 |
| Eisai Inc. Oct 1, 2025 | Consulting Fee Leqembi · Neurology | $3,520 |
| Roche Diagnostics Corporation Nov 25, 2025 | Consulting Fee None | $3,348 |
| Lilly USA, LLC Sep 16, 2025 | Consulting Fee KISUNLA · Neuroscience | $1,563 |
| Lilly USA, LLC Oct 31, 2025 | Consulting Fee KISUNLA · Neuroscience | $950 |
| Eli Lilly and Company Nov 17, 2025 | Compensation for services other than consulting (speaking, faculty) | $950 |
| Lilly USA, LLC Jan 15, 2025 | Travel and Lodging KISUNLA · Neuroscience · travel to CHARLOTTE, NC | $420 |
| Lilly USA, LLC Jan 15, 2025 | Travel and Lodging KISUNLA · Neuroscience · travel to CHARLOTTE, NC | $64.06 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Roche Diagnostics Corporation Nov 25, 2025 | Consulting Fee None | $3,348 |
| Eli Lilly and Company Nov 17, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,625 |
| Eli Lilly and Company Nov 17, 2025 | Compensation for services other than consulting (speaking, faculty) | $950 |
| Lilly USA, LLC Oct 31, 2025 | Consulting Fee KISUNLA · Neuroscience | $9,375 |
| Lilly USA, LLC Oct 31, 2025 | Consulting Fee KISUNLA · Neuroscience | $950 |
| Eisai Inc. Oct 1, 2025 | Consulting Fee Leqembi · Neurology | $3,520 |
| Lilly USA, LLC Sep 16, 2025 | Consulting Fee KISUNLA · Neuroscience | $1,563 |
| AbbVie Inc. Feb 10, 2025 | Consulting Fee | $7,200 |
| AbbVie Inc. Jan 17, 2025 | Travel and Lodging travel to INDIANAPOLIS, IN · in-kind | $42.88 |
| AbbVie Inc. Jan 17, 2025 | Travel and Lodging travel to INDIANAPOLIS, IN · in-kind | $28.00 |
| Lilly USA, LLC Jan 15, 2025 | Travel and Lodging KISUNLA · Neuroscience · travel to CHARLOTTE, NC | $420 |
| Lilly USA, LLC Jan 15, 2025 | Travel and Lodging KISUNLA · Neuroscience · travel to CHARLOTTE, NC | $64.06 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $321,911 in research payments for these studies, mostly to the institutions running them.
- A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Eisai Inc. - A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
Alnylam Pharmaceuticals Inc. - A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Eli Lilly and Company · Active, not recruiting · NCT04437511
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.